Expression of GADS enhances FLT3-induced mitogenic signaling

Oncotarget
Rohit A ChouguleJulhash U Kazi

Abstract

GADS is a member of a family of SH2 and SH3 domain-containing adaptors that functions in tyrosine kinase-mediated signaling cascades. Its expression is largely restricted to hematopoietic tissues and cell lines. Therefore, GADS is mainly involved in leukocyte-specific protein tyrosine kinase signaling. GADS is known to interact with tyrosine-phosphorylated SHC, BCR-ABL and KIT. The SH2 domain of GADS has a similar binding specificity to that of GRB2 but its SH3 domain displays a different binding specificity, and thus it is involved in other downstream signaling pathways than GRB2. In the present study, we examined the role of GADS in FLT3 signaling. FLT3 is a type III receptor tyrosine kinase, which is mutated in more than 30% of acute myeloid leukemia (AML) and the most common mutations is the internal tandem duplication (ITD) mutations. We observed that expression of GADS enhanced oncogenic FLT3-ITD-induced cell proliferation and colony formation in vitro. In a mouse xenograft model, GADS accelerated FLT3-ITD-dependent tumor formation. Furthermore, expression of GADS induced a transcriptional program leading to upregulation of MYC and mTORC1 target genes. GADS localizes to the cell membrane and strongly binds to ligand-stimu...Continue Reading

References

Mar 12, 1993·Cell·Z SongyangR J Lechleider
Jan 27, 1995·Cell·G B CohenD Baltimore
May 24, 1996·The Journal of Biological Chemistry·G S FengJ Ni
May 23, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J H EllisP A Hamblin
Oct 19, 2001·Oncogene·S K LiuC J McGlade
Aug 15, 2002·Blood·D Gary Gilliland, James D Griffin
Sep 9, 2005·International Journal of Hematology·Chunaram ChoudharyHubert Serve
Feb 24, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ji-Eun Kim, Forest M White
Jul 5, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ryosuke WatanabeRyo Abe
Oct 2, 2007·Experimental Cell Research·Jianmin SunLars Rönnstrand
May 15, 2009·British Journal of Haematology·Kristina MassonLars Rönnstrand
May 30, 2009·Experimental Hematology·Elena RazumovskayaLars Rönnstrand
Jun 23, 2009·Cellular Signalling·Kristina Masson, Lars Rönnstrand
Sep 4, 2012·Blood·De-Chen LinH Phillip Koeffler
Jan 22, 2013·Medical Oncology·Nuzhat N KabirJulhash U Kazi
Jan 15, 2014·Molecular Biology Reports·Nuzhat N Kabir, Julhash U Kazi
Feb 15, 2014·Cancer Cell·Alexandre PuissantKimberly Stegmaier
Apr 8, 2014·Cellular and Molecular Life Sciences : CMLS·Julhash U KaziLars Rönnstrand
Aug 31, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Nuzhat N KabirJulhash U Kazi
Mar 17, 2015·Cellular and Molecular Life Sciences : CMLS·Julhash U KaziLars Rönnstrand
Jun 6, 2015·Oncotarget·Oscar LindbladJulhash U Kazi

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
xenografts
immunoprecipitation
pull-down
pull down
confocal microscopy
ubiquitination
transfection
transfections

Software Mentioned

GraphPad
ImageJ

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.